Europe

Dr Gould brings her substantial expertise and network to the anti-infective company at a crucial time, ahead of entering the clinical stage with lead candidate NOSO-502
BioArctic AB has been awarded a grant from EU’s research and innovation program Horizon 2020.
FDA
YUPELRI (revefenacin) is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US
Medtronic plc announced today that it will report financial results for the second quarter of fiscal year 2019 on Tuesday, November 20, 2018. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at http://newsroom.medtronic.com.
During the annual congress of the French Society of Pathology which is held held from 5th to 8th November 2018 in Paris, AP-HP, Greater Paris University Hospitals and TRIBVN Healthcare are pleased to announce a 5-year strategic partnership to develop and operate a National Telepathology Platform.
Promore Pharma AB today announced the composition of the Nomination Committee for the Annual General Meeting 2019, which will be held on Tuesday 21 May 2019.
Even with the Thanksgiving week, there is interesting and exciting research being conducted and published. Here’s a look.
An ovarian cancer treatment co-developed by Germany’s Merck KGaA and Pfizer failed to meet endpoints for overall survival and progression-free survival in a Phase III trial.
PRESS RELEASES